Explore evidence

85.6 %An efficient viral load reduction to below 50 copies/ml was observed in 113 (85.6%) of the 132 patients who had been on ART for more than 6 months.

KenyaVIH/sidapublished 2009AIDS research and therapyeurope_pmcdocument of 8 observations

18 %Late ART refills occurred at 18% of postpartum visits among HIV-seropositive Kenyan women.

KenyaVIH/sidapublished 2021PloS oneeurope_pmcdocument of 2 observationsDOI 10.1371/journal.pone.0254767

18 %In a pragmatic randomized trial in rural western Kenya, disengagement from HIV care was 18% in the intervention group and 17% in the control group over one year of follow-up.

KenyaVIH/sidaobserved one year of follow-uppublished 2021PloS onePubMeddocument of 9 observations

90 %A modest 20-40% reduction in endogenous IRF-1 in ex vivo-derived peripheral CD4(+) T cells and monocytes resulted in >90% reduction in the transactivation of the HIV-1 genes (Gag, p24) and, hence, HIV replication.

KenyaVIH/sidapublished 2015Molecular therapy. Nucleic acidseurope_pmcdocument of 2 observations

80 %At baseline, 60 out of 75 participants living with HIV (80%) had previously enrolled in HIV care.

KenyaVIH/sidapublished 2023BMC health services researchPubMeddocument of 12 observations

1.23 aHRAmong sexual contacts of HIV-positive index clients in Siaya County, Kenya, non-spouse sexual contacts had an adjusted hazard ratio of 1.23 for HIV testing compared to spouse sexual contacts.

KenyaVIH/sidaobserved June 2017-August 2018published 2020PloS onePubMeddocument of 8 observations

7 %7% of HIV-1 transmission clusters were mixed between heterosexuals and men who have sex with men (HET/MSM).

KenyaVIH/sidaobserved 2005-2019published 2020Scientific reportsPubMeddocument of 9 observations

1.6 %Viral load monitoring reduced vertical transmission by 1.6–2.7% in newly positive women in Kenya.

KenyaVIH/sidapublished 2025AIDS (London, England)PubMeddocument of 6 observations

0.7 per_100_person_monthsThe overall rate of first viral rebound was 0.7 per 100 person-months in Malindi.

KenyaVIH/sidapublished 2020International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument of 9 observations

287 clientsFrom November 2020 to October 2021, 287 out of 476 eligible clients were initiated on PrEP at private pharmacies in Kenya.

KenyaVIH/sidaobserved November 2020 to October 2021published 2023Journal of the International AIDS Societyeurope_pmcdocument of 12 observationsDOI 10.1002/jia2.26131

17 %Among 600 sexually active women living with HIV aged 18–69 attending the Comprehensive Care Clinic at Kenyatta National Hospital in Nairobi, 17% experienced physical violence.

KenyaVIH/sidaobserved 2012published 2020Health and human rightsPubMeddocument of 4 observations

82.3 %HIV-1 drug resistance mutations were found in 82.3% of the subjects.

KenyaVIH/sidapublished 2021MedicinePubMeddocument of 11 observations

98.5 %The sensitivity of provider-delivered HIVST at the pharmacy was 98.5% when interpreted by providers.

KenyaVIH/sidaobserved between March and June 2022published 2023Journal of the International AIDS SocietyPubMeddocument of 9 observations

Kaposi's sarcoma is one of the most common HIV-associated cancers in sub-Saharan Africa.

KenyaKaposi's sarcoma · VIH/sidapublished 2022Journal of the International AIDS SocietyPubMeddocument of 4 observations

89 participantsBetween July 15, 2021, and Nov 2, 2022, 89 healthy adults living without HIV-1 were randomly assigned.

KenyaVIH/sidaobserved July 15, 2021 to Nov 2, 2022published 2025The Lancet. MicrobePubMeddocument of 9 observations

90 %The proportion of adolescents and young people living with HIV on antiretroviral therapy with unsuppressed viral load who completed three enhanced adherence counselling sessions rose to 90% in the final month of the implementation period.

KenyaVIH/sidaobserved July 2020published 2022BMJ open qualityPubMeddocument of 8 observations

90.1 %Among 4708 PLHIV initiated on IPT in Kenya between July 2015 and June 2018, 4,243 (90.1%) had documentation of tuberculosis screening on the IPT tool before IPT initiation.

Kenyatuberculose · VIH/sidaobserved July 2015 to June 2018published 2020PloS onePubMeddocument of 8 observations

56.7 %Treatment interruptions ≥48 hours during the past 6 months were reported by 56.7% of patients in the Democratic Republic of Congo.

KenyaVIH/sidapublished 2021Journal of acquired immune deficiency syndromes (1999)PubMeddocument of 14 observations

13.84 per_1000_person-yearsHIV incidence among adults without HIV in Kisumu County, Kenya, was 13.84 per 1000 person-years in the first year of follow-up between January 2017 and August 2021.

KenyaVIH/sidaobserved first year of follow-uppublished 2026PloS onePubMeddocument of 7 observations

28.5 %Over one quarter (28.5%) of decedents received by high-volume mortuaries in western Kenya were HIV-positive.

KenyaVIH/sidapublished 2021PloS onePubMeddocument of 14 observations

0.3 %The percentage of HIV infections with PrEP-associated nucleoside reverse transcriptase inhibitor (NRTI) drug resistance was 0.3% in the antibody rapid diagnostic testing scenario.

KenyaVIH/sidapublished 2024The lancet. HIVPubMeddocument of 6 observations

78 %78% of the participants preferred full disclosure of their HIV status by 12 years of age.

KenyaVIH/sidaobserved 2019published 2023Frontiers in public healthPubMeddocument of 18 observations

3.9 per_100_person_monthsThe overall rate of first viral rebound was 3.9 per 100 person-months in Nakuru.

KenyaVIH/sidapublished 2020International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument of 9 observations

92 %Among HIV-infected children in Kenya, 92% were receiving antiretroviral therapy (ART) in 2018.

KenyaVIH/sidaobserved 2018published 2022PloS onePubMeddocument of 10 observations

3.64 prevalence_rate_ratioThe prevalence rate ratio for HIV counseling in intervention versus control facilities in the final study quarter was 3.64.

KenyaVIH/sidapublished 2022Implementation science : ISeurope_pmcdocument of 6 observationsDOI 10.1186/s13012-022-01242-3